



How the pharmaceutical industry is tackling 'severe' suffering in animals used in science

An online event co-organised by EFPIA and the RSPCA

Wednesday 26 January 2022: 14:30 - 16.00 CET

About this event

Any level of animal suffering is obviously a concern for everyone, but suffering classified¹ as 'severe' is of greatest concern. There is widespread support within the scientific community for working to reduce, and ideally end, severe suffering. This free 90-minute webinar will share and showcase some of the positive and practical steps that have been taken by the pharmaceutical industry aimed at avoiding or reducing 'severe' suffering in animals used in research and testing. The event will include case study examples and a panel discussion of some current challenges and how these are being overcome.

Register [here](#) before the 24th January



¹ e.g. under EU Directive 2010/63/EU

Agenda

14.30	Welcome - Kirsty Reid, EFPIA and Barney Reed, RSPCA
	Update on the RSPCA's 'Focus on severe suffering' initiative - Barney Reed, RSPCA
14.40	Tackling severe suffering within the context of EFPIA's vision, aims and activities - Kirsty Reid, EFPIA
Case study examples - approaches to avoiding and reducing severe suffering	
14.50	A new group housing approach for non-human primates in metabolism studies - John Kendrick, Labcorp
15:05	Refining and reducing animal use in challenge potency tests - Emmanuelle Coppens, Sanofi
15:20	Refining animal use in Maximum Tolerated Dose studies - Thomas Bertelsen, Novo Nordisk
Questions and panel discussion	
15:35	Challenges and progress towards avoiding and reducing severe suffering
15:55	Concluding comments
16:00	End

Resources and further information

1. RSPCA website 'Focus on severe suffering': www.focusonseveresuffering.co.uk
2. A 'roadmap' to reducing severe suffering: a practical exercise to help institutions focus on procedures that could cause 'severe' suffering, identify contributing factors and find ways of avoiding or refining these: www.focusonseveresuffering.co.uk/roadmap
3. Stow et al (2020). A new group housing approach for non-human primate metabolism studies. <https://doi.org/10.1016/j.vascn.2020.106947>
4. Bandiera et al (2019). A single immunogenicity assay for testing potency of combination DTaP vaccines: Simultaneous quantitation of anti-DT, anti-TT, anti-PTxd and anti- FHA antibodies in Guinea-pig serum with a Luminex®-xMAP® bead-based serological assay. <https://doi.org/10.1016/j.biologicals.2019.08.002>